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Objectives. We report the occurrence of cardiac events during
long-term follow-up in patients with hypertrophic cardiomyopathy
(HCM) after cardioverter-defibrillator implantation.
Background. The identification of patients at high risk for
sudden death and the prevention of recurrence of sudden death in
HCM represents a difficult problem.
Methods. We retrospectively analyzed the occurrence of cardiac
events during follow-up of 13 patients with HCM who received an
implantable cardioverter-defibrillator (ICD) because of aborted
sudden death (n 5 10) or sustained ventricular tachycardia (n 5
3) (group I). Findings were compared with those in 215 patients
with an ICD and other structural heart disease or idiopathic
ventricular fibrillation (group II).
Results. After a mean (6SD) follow-up period of 26 6 18
months, 2 of 13 patients in group I received appropriate shocks.
The calculated cumulative incidence of shocks was 21% in group
I and 66% in group II after 40 months (p < 0.05). We observed a
low incidence of recurrence of ventricular tachycardia/fibrillation
during follow-up in patients with HCM. No deaths occurred.
Conclusions. Our data suggest that ventricular tachyarrhyth-
mias may not always be the primary mechanism of syncope and
sudden death in patients with HCM. The ICD seems to have a less
important impact on prognosis in patients with HCM than in
patients with other etiologies of aborted sudden death.
(J Am Coll Cardiol 1998;31:1081–5)
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Hypertrophic cardiomyopathy (HCM) is characterized by a
partial or global hypertrophy of the left ventricle not caused by
known diseases or conditions (1). The disease is transmitted
with an autosomal dominant pattern of inheritance. Different
genes have been related to the disease, and one single gene
may be related to different phenotypic expressions, which may
partly explain the remarkable anatomopathologic and clinical
heterogeneity of the disease (2,3).
The natural history of HCM is usually characterized by a
slow progression of symptoms such as angina or dyspnea or the
occurrence of syncope. In contrast, sudden death may occur
abruptly, with a particularly high incidence in children and
young adults (4). Most patients are asymptomatic or only
mildly symptomatic before the first episode of aborted sudden
death.
The role of the implantable cardioverter-defibrillator (ICD)
in preventing sudden death in patients with HCM is unclear.
The present study sought to assess the role of the ICD in
patients with HCM who survived a first episode of sudden
death. The findings in this patient group were compared with
the occurrence of events in two other groups: patients with an
ICD and structural heart disease (other than HCM) and
patients with idiopathic ventricular fibrillation (structurally
normal heart).
Methods
Patients. Group I. We retrospectively studied 13 patients
with HCM (group I) and an ICD (eight men, five women;
mean [6SD] age 48 6 13 years). Five patients (39%) had
hypertrophic obstructive cardiomyopathy, and all but one had
asymmetric left ventricular wall hypertrophy. The maximal
thickness of the affected wall was 25 6 2 mm. All patients had
normal coronary arteries. One patient had a minor systolic
bridging in the left anterior descending coronary artery (5).
Mean left ventricular ejection fraction (LVEF) was 65 6 12%,
and only one patient had abnormal systolic function (LVEF
40%).
The indication for ICD therapy was resuscitated sudden
death with documented ventricular fibrillation during the
aborted episode in 10 patients (77%), recurrent syncope with
inducible polymorphic ventricular tachycardia or ventricular
fibrillation during electrophysiologic evaluation in 2 patients
(15%) and multiple episodes of sustained monomorphic ven-
tricular tachycardia in the remaining patient. Programmed
electrical stimulation of the heart was performed in all patients
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and was positive in seven (54%). The clinical characteristics
and main echocardiographic findings of the patients are shown
in Table 1.
All patients underwent ICD implantation with a trans-
venous lead system, and no complications were seen in the
early postoperative period, with the exception of an early lead
displacement in one patient. Two patients underwent elective
generator replacement because of battery exhaustion. No
device-related problems occurred during a mean follow-up
period of 26 6 18 months. After ICD implantation, 11 patients
received antiarrhythmic drugs (Table 2).
Group IIA. Another 196 patients were analyzed (163 with
ischemic heart disease, 33 with dilated nonischemic cardiomy-
opathy; mean age 63 6 9 years, 88% male). The indications for
ICD implantation were aborted sudden death in 80 patients
(41%), syncopal ventricular tachycardia in 67 (34%) and
medically uncontrollable ventricular arrhythmias in 43 (22%).
In 3% of patients a prophylactic ICD implantation was per-
formed because of poor left ventricular function in combina-
tion with inducible ventricular arrhythmias during electro-
physiologic study. The mean LVEF in group IIA was 36 6
15%. The mean follow-up period after ICD implantation was
24 6 21 months.
Group IIB. A third group of patients with idiopathic ven-
tricular fibrillation were also analyzed. There were 19 patients
(90% male, mean age 39 6 14 years) with a structurally normal
heart, normal LVEF (71 6 10%), normal left and right
ventricles and normal coronary arteries. Twelve patients had
an ICD implanted because of aborted sudden death (63%).
The other six patients (32%) had syncopal sustained polymor-
phic ventricular arrhythmias. The remaining patient was an
asymptomatic young patient with a family history of sudden
death and an electrocardiogram (ECG) showing right bundle
branch block, persistent ST segment elevation and easily
inducible ventricular fibrillation (6). The follow-up period was
39 6 20 months.
Shock occurrence and appropriateness or inappropriate-
ness of therapy was assessed by analyzing the intracardiac
electrograms or the RR intervals, or both, at the time of shock.
Ninety-two percent of the total ICD group and 100% of
patients with HCM had devices with capability for electrogram
storage or RR interval analysis.
Statistical analysis. Kaplan-Meier analysis was performed
to predict the incidence of the first appropriate shock at any
time for a group, and the log rank test was performed to
compare the study group with the other patient groups. The
Student t test, Fisher exact test and chi-square analysis were
used to compare the different study groups, respectively, for
continuous and noncontinuous variables. Results are pre-
sented as mean value 6 SD; p , 0.05 was considered signifi-
cant.
Results
During the follow-up period of 26 6 18 months, only 2 of 13
patients with HCM received appropriate shocks because of two
episodes of sustained monomorphic ventricular tachycardia in
one patient and several episodes of sustained polymorphic
ventricular tachycardia or ventricular fibrillation in another.
Abbreviations and Acronyms
ECG 5 electrocardiogram
HCM 5 hypertrophic cardiomyopathy
ICD 5 implantable cardioverter-defibrillator
LVEF 5 left ventricular ejection fraction
Table 1. Clinical Manifestations and Diagnostic Study Results in 13 Patients With Hypertrophic
Cardiomyopathy
Pt No./Gender
Age
(yr) Sync CA
Holter
Monitoring HOCM Wall
LVEF
(%) PES
1/M 35 1 1 rare nsVT Yes IVS 75 2
2/F 47 1 1 VEB No IVS 70 2
3/M 60 2 2 sVT No IVS 50 1
4/M 33 2 1 VEB Yes IVS 71 2
5/F 49 2 1 No Inf-Ap 55 2
6/F 60 1 1 nsVT No Con 80 2
7/M 48 2 1 sVT No IVS-Ap 78 1
8/M 54 1 2 nspmVT Yes IVS 60 1
9/M 52 2 1 nsVT Yes IVS 76 1
10/F 15 1 1 nsVT No IVS 60 1
11/M 45 2 1 nsVT No IVS 65 1
12/M 63 1 2 VEB No IVS-Dil 40 1
13/F 58 2 1 VEB Yes IVS 70 2
Ap 5 apex; CA 5 cardiac arrest; Con 5 concentric wall hypertrophy; Dil 5 left ventricular chamber dilation; F 5
female; HCOM 5 hypertrophic obstructive cardiomyopathy; Inf 5 inferior wall; IVS 5 interventricular septum; LVEF
5 left ventricular ejection fraction; M 5 male; ns 5 nonsustained; PES 5 programmed electrical stimulation; pm 5
polymorphic; Pt 5 patient; s 5 sustained; Sync 5 syncope; VEB 5 ventricular ectopic beats; VT 5 ventricular
tachycardia; Wall 5 segment affected; 1/2 5 positive/negative.
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The second of these two patients had previously been resusci-
tated.
Group IIA patients were older than group I patients (63 6
9 vs. 48 6 13 years, p , 0.001), but there were no age
differences between groups I and IIB (48 6 13 vs. 38 6 14
years, p 5 NS).
Group IIA patients also had a worse LVEF than group I
patients (36 6 14% vs. 65 6 12%, p , 0.001). LVEF was
comparable in groups I and IIB (65 6 12% vs. 71 6 10%, p 5
NS).
The calculated cumulative occurrence of appropriate
shocks in patients with HCM (group I) was 21% at 47 months
of follow-up, significantly different from the cumulative occur-
rence of the first shock of 65% at 47 months for patients with
a structurally normal heart and ventricular fibrillation (group
IIB). The cumulative occurrence of shocks in patients with
structural heart disease (group IIA) was also significantly
higher, with 68% at 47 months of follow-up. Figures 1 and 2
show the Kaplan-Meier curves for shock occurrence in the
different groups.
We also analyzed the subgroup of patients with ICD
implantation after aborted sudden death (10 patients in group
I, 80 in group IIA, 12 in group IIB), and we constructed
Kaplan-Meier curves for the occurrence of the first appropri-
ate shock in each subgroup. As can be seen in Figure 3, the
cumulative incidence of first shock in group IIA and IIB
patients with aborted sudden death was, respectively, 62% and
67% versus only 11% in resuscitated group I patients at 40
months (p , 0.05).
Three patients with HCM (23%) had inappropriate shocks
because of fast atrial arrhythmias, which was comparable to the
incidence of inappropriate shocks in group IIB (21%, p 5 NS)
but significantly higher than the occurrence of inappropriate
therapy in group IIA (6%, p , 0.05).
No deaths occurred in the study group. The total mortality
rate during follow-up was 11% (26 patients) and occurred
exclusively in group IIA.
Discussion
Risk stratification in hypertrophic cardiomyopathy. The
identification of individual patients with HCM at high risk for
sudden death and prevention of recurrence represents an
unsolved problem in clinical cardiology.
Several factors have limited our ability to accurately stratify
this risk. The disease prevalence is low, although probably
underestimated (0.2% in the general population), and most
published reports come from tertiary referral centers, intro-
ducing important selection biases (3). Furthermore, HCM
seems to be a collection of different disease entities sharing
certain morphologic characteristics.
There are several characteristics that seem to be associated
with a worse prognosis: young age at clinical presentation, a
positive family history of sudden death (which is also associ-
ated with particular genetic mutations) and a history of
(pre)syncope or resuscitated sudden death. The presence of
exercise-induced hypotension and nonsustained ventricular
tachycardia in Holter monitoring would predict a poor prog-
nosis (3). However, all these prognostic indicators have a low
sensitivity and positive predictive accuracy that can be im-
proved somewhat by combining several factors. Also, the
presence of inducible ventricular arrhythmias at programmed
electrical stimulation of the heart has a varying predictive
accuracy, depending on the aggressiveness of the stimulation
protocol (7,8).
Value of ICD therapy. We studied a group of patients with
HCM highly selected in terms of risk because they underwent
ICD implantation after such symptoms as impaired conscious-
Table 2. Events During Follow-Up in Patients With an Implantable Cardioverter-Defibrillator and
Hypertrophic Cardiomyopathy
Pt
No.
ICD
Model
DFT
(J)
No. of
Appropriate
Shocks
Inappropriate
Shocks
Therapy
Before
Implant
Therapy
After
Implant
Follow-Up
(mo)
1 P2 10 — No Sot Sot 30
2 JEW 15 10 No No Amio; Sot 15
3 PRx 20 2 Yes DDD pacing DDD pacing 58
4 P2 15 — Yes Amio Met 65
5 JEW 10 — No Amio Met 34
6 MIN HC 15 — No Vera No 9
7 JEW 15 — No Amio Amio 30
8 P2 5 — No Amio; Prop Prop 42
9 MIN 5 — No Vera Vera 16
10 PRx III 5 — Yes Amio Amio; Vera 26
11 MINI 8 — No Aten Sot; Nif 11
12 MINI II 5 — No Amio Amio 8
13 MINI II 10 — No Amio; Vera Aten 3
Amio 5 amiodarone; Aten 5 atenolol; DFT 5 defibrillation threshold test; ICD 5 implantable cardioverter-
defibrillator; Implant 5 ICD implantation; JEW 5 Medtronic Jewel; Met 5 metoprolol; MIN 5 CPI Ventak Mini; Nif 5
Nifedipine; P2 5 CPI Ventak P2; Prop 5 propanolol; PRx 5 CPI Ventak Prx; Pt 5 patient; Sot 5 sotalol; Vera 5
verapamil.
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ness, aborted sudden death or syncope. In an isolated case,
symptomatic and sustained ventricular tachycardia in ambula-
tory ECG monitoring not suppressed by antiarrhythmic drug
therapy was the indication for ICD implantation. Furthermore,
ventricular fibrillation was documented during resuscitation in
all patients, and in the two patients with syncope there were
inducible ventricular tachycardias during programmed electri-
cal stimulation of the heart.
We thus expected these patients to have the same benefit of
ICD therapy as patients with ischemic heart disease and
dilated cardiomyopathy (group IIA) or patients with an ICD
and idiopathic ventricular fibrillation (group IIB). However,
the number of patients with HCM who received shocks was
only 2 of 13 after a mean follow-up of .2 years. We noted an
important difference in cumulative occurrence of shocks in the
different ICD groups, as well as in the subgroups with a history
of aborted sudden death (Fig. 1 to 3)
These data suggest that ventricular arrhythmias may not
always be the primary mechanism of syncope or sudden death
in these patients. Although ventricular fibrillation was docu-
mented in all resuscitated patients, ventricular arrhythmias can
be triggered by ischemia, outflow tract obstruction, arterial
hypotension, diastolic dysfunction, proarrhythmic effects of
antiarrhythmic drugs, sinus tachycardia during exercise or
supraventricular tachyarrhythmias, such as atrial fibrillation
(3–9).
Other mechanisms of syncope in HCM are known, such as
bradyarrhythmias due to sinus node dysfunction or atrioven-
tricular block or vasovagal mechanisms (10). Serious bradycar-
dias were also documented in two of our patients before or
after ICD implantation.
Because survival was 100% in our study group, we can
speculate whether the “inappropriate shocks” for atrial fibril-
lation were sometimes perhaps “appropriate therapy” because
it has been shown (4) that atrial fibrillation in patients with
HCM can trigger malignant ventricular tachyarrhythmias.
Also, antibradycardia pacing by the device could potentially
have been life-saving in some patients.
Study limitations. There are several limitations that should
be kept in mind when interpreting our findings. The study was
a retrospective analysis, and although we evaluated a total of
.200 patients with an ICD, this number is relatively small.
However, to our knowledge there are no reports on the results
of ICD therapy in larger groups of patients with HCM.
The analysis is confounded by the continuing use of antiar-
rhythmic drugs, but no significant difference in the use of these
drugs before or after ICD implantation was noted.
Although the mean follow-up period exceeds 2 years, it is
possible that with a longer follow-up period, a larger number of
patients will have a recurrences. We therefore want to caution
against interpreting the lower incidence of shocks in this
cohort as evidence that ICD therapy is less indicated in
patients with life-threatening ventricular tachyarrhythmias and
HCM.
Conclusions. Our patients with HCM and sustained ven-
tricular tachyarrhythmias had a lower incidence of recurrence
Figure 1. Cumulative occurrence of the first shock (Kaplan-Meier
analysis) in patients with an ICD (group I) and patients with other
forms of structural heart disease (group IIA). The cumulative occur-
rence of shocks was 68% in group IIA and 21% in group I after 47
months of follow-up.
Figure 2. Cumulative occurrence of the first shock (Kaplan-Meier
analysis) in patients with HCM (group I) and patients with idiopathic
ventricular tachycardia/ventricular fibrillation (group IIB). After 47
months of follow-up, the cumulative occurrence of first shock was 65%
in group IIB and 21% in group I.
Figure 3. Cumulative occurrence of the first shock in patients with
resuscitated sudden death (Kaplan-Meier analysis). The calculated
cumulative occurrence of shocks was 62% in group IIA, 67% in group
IIB and 11% in group I after 40 months of follow-up (p 5 0.0375 for
group I vs. group IIA and p 5 0.0372 for group I vs. group IIB by log
rank test). Groups I, IIA and IIB as in Figures 1 and 2.
1084 PRIMO ET AL. JACC Vol. 31, No. 5
ICD IN HYPERTROPHIC CARDIOMYOPATHY April 1998:1081–5
than did other patients with an ICD during a mean follow-up
period of .2 years. These data suggest that ventricular ar-
rhythmias may not always be the primary mechanism of
syncope or sudden death in patients with HCM.
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